Graphene Oxide in Vaccines: Research Evidence
Yes, there are multiple peer-reviewed studies investigating graphene oxide as a vaccine adjuvant and delivery vehicle, demonstrating its potential to enhance both humoral and cellular immune responses across various vaccine platforms.
Current Research Landscape
The scientific literature contains substantial evidence examining graphene oxide (GO) in vaccine development, though it is important to clarify that graphene oxide is NOT present in any currently approved commercial vaccines, including COVID-19 vaccines 1. The approved mRNA vaccines (Pfizer/BioNTech and Moderna) use lipid nanoparticles composed of cholesterol, structural lipids, PEGylated lipids, and proprietary cationic ionizable lipids—not graphene oxide 1.
Experimental Vaccine Studies with Graphene Oxide
Influenza Vaccines
Research demonstrates that self-assembled graphene oxide quantum dots combined with carnosine, resiquimod, and Zn²⁺ ions (ZnGC-R) as an adjuvant produced remarkable results in influenza vaccination 2:
- Generated 2.53-fold higher hemagglutination-inhibiting antibody titers compared to aluminum salt adjuvants
- Elicited 342% stronger IgG antibody responses versus inactivated virus alone
- Achieved 100% protection efficacy against H1N1 influenza virus challenge in animal models
- Enhanced both CD4+ T follicular helper cells and CD8+ effector memory T cell responses
Hepatitis E Virus (HEV) Vaccines
Chitosan-functionalized graphene oxide (GO-CS) combined with HEV P239 protein demonstrated enhanced immune responses compared to protein-only vaccines, stimulating both cellular and humoral immunity with acceptable safety profiles in preclinical testing 3.
COVID-19 Vaccine Research
Large-sized graphene oxide nanosheets (>1 μm diameter) showed promising results as dendritic cell vaccine adjuvants 4:
- Enhanced DC-T cell synapse formation through cytoskeletal reorganization via the RhoA-ROCK-MLC pathway
- Achieved >99.7% viral RNA clearance in mice infected with clinically isolated SARS-CoV-2
- Acted as a "nanozipper" facilitating DC-T cell cluster aggregation for robust cytotoxic T cell responses
Cancer Immunotherapy
GO-based platforms have been investigated for personalized cancer vaccines 5, 6:
- Injectable GO-polyethylenimine hydrogels generated mRNA nanovaccines lasting 30+ days
- Reduced graphene oxide nanosheets achieved 15-20% lymph node accumulation (>100-fold improvement over soluble vaccines)
- Single injections elicited potent neoantigen-specific T cell responses lasting 30 days
Mechanisms of Action
Graphene oxide functions as a vaccine adjuvant through multiple pathways 7:
- Large surface area enables high antigen-loading capacity
- Enhances dendritic cell recruitment and activation
- Induces intracellular reactive oxygen species, guiding antigen processing and presentation
- Stimulates innate immune responses and inflammatory factors
- Improves antigen presentation to CD8+ T cells
Safety Considerations
Human Safety Data
A first-in-human controlled inhalation study of graphene oxide nanosheets (200 μg/m³ for 2 hours) in 14 healthy volunteers found 8:
- No adverse effects or overt detrimental effects
- No changes in heart rate, blood pressure, lung function, or inflammatory markers
- Mild increase in thrombus formation in ex vivo arterial injury models
- Overall well-tolerated exposure
Potential Concerns
Research indicates that GO injection can induce oxidative stress and inflammation 7. Surface functionalization protocols (PEGylation, chitosan modification) have been developed to:
- Reduce aggregation in biological fluids
- Minimize cell death induction
- Improve biocompatibility
- Enhance therapeutic properties
Clinical Translation Status
Graphene oxide remains in preclinical and early research phases for vaccine applications 9, 7. Critical barriers to clinical translation include:
- Scalability challenges for industrial production
- Cost-effectiveness concerns
- Need for comprehensive long-term safety data
- Ecological safety assessments
- Standardization of synthesis methods
Key Distinctions
The evidence clearly demonstrates that while graphene oxide is being actively researched as a potential vaccine adjuvant with promising preclinical results, it is not currently used in any approved human vaccines. The nanoparticle platforms in approved vaccines utilize entirely different materials, primarily lipid-based formulations 1.